Elevance Health, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NYSE
Elevance Health reported 13% operating revenue growth to $197.6 billion in 2025, alongside strategic advancements in its whole health approach and corporate governance.
NYSE
Elevance Health announces its annual shareholder meeting to be held virtually on May 14, 2025, covering director elections, executive compensation, auditor ratification, and a DEI report proposal.
NYSE
Elevance Health announces its annual shareholder meeting to be held virtually on May 14, 2025, with key proposals including director elections and executive compensation.
NYSE
Elevance Health's proxy statement outlines the company's 2024 performance, 2025 growth plans, and corporate governance practices.
NYSE
Elevance Health files a supplement to its proxy statement to correct an error in the Summary Compensation Table, which omitted a one-time cash award to the CFO, Mark B. Kaye.
NYSE
Elevance Health, Inc. has filed a definitive proxy statement with the SEC.
NYSE
Elevance Health's proxy statement details the company's 2023 performance, including revenue growth and strategic initiatives, and outlines plans for the 2024 annual meeting.